Anidulafungin: an echinocandin antifungal (Q35871936)

10 August 2017

1 reference

title

Anidulafungin: an echinocandin antifungal (English)

1 reference

10 August 2017

Michael A Pfaller

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Expert Opinion on Investigational Drugs

10 August 2017

published in

1 reference

10 August 2017

1 reference

10 August 2017

1 reference

10 August 2017

page(s)

1183-1197

1 reference

Update on antifungals targeted to the cell wall: focus on beta-1,3-glucan synthase inhibitors

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Caspofungin: first approved agent in a new class of antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Clinical efficacy of echinocandin antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Antibiotics that inhibit fungal cell wall development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

In vitro activity of anidulafungin against selected clinically important mold isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

The natural history of esophageal candidiasis after successful treatment in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Has antifungal susceptibility testing come of age?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Antifungal susceptibility testing: practical aspects and current challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.9.1183

10.1517/13543784.13.9.1183

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference